{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T21:47:04Z","timestamp":1779400024030,"version":"3.53.1"},"reference-count":65,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,12,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Improved understanding of the molecular underpinnings of acute leukemia has led to advances in the detection of very low levels of leukemia-specific abnormalities, known as measurable residual disease (MRD). The limit of detection for modern next-generation sequencing and polymerase chain reaction\u2013based assays is as low as 10\u20136, allowing for quantitative and longitudinal monitoring in both acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). In the period surrounding allogeneic hematopoietic cell transplantation (HCT), detectable MRD is clearly associated with poor outcomes, primarily due to an increased risk of morphologic relapse. In this review, we address the use of maintenance therapy for patients with acute leukemia, including those who are MRD-positive prior to and following HCT. Post-HCT azacitidine may have a role for MRD-positive AML. In AML with FLT3\u2013internal tandem duplication mutation, post-HCT gilteritinib and sorafenib can be evidence-based strategies to target MRD. In ALL, blinatumomab is a powerful tool to eradicate MRD in patients with Philadelphia (Ph)-positive or Ph-negative ALL; tyrosine kinase inhibitors are indicated for post-HCT management of Ph+ ALL. Despite these advances, the optimal duration and type of intervention still remain unknown for many patients with acute leukemia who have peri-HCT MRD.<\/jats:p>","DOI":"10.1182\/hematology.2025000745","type":"journal-article","created":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T14:09:42Z","timestamp":1764943782000},"page":"523-530","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":1,"title":["Peri-transplant conundrums: optimizing maintenance therapy using MRD-directed approaches"],"prefix":"10.1182","volume":"2025","author":[{"given":"Suravi","family":"Raychaudhuri","sequence":"first","affiliation":[{"name":"1 Division of Hematology and Oncology, Department of Medicine, University of Washington, Seattle, WA"},{"name":"2 Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan D.","family":"Cassaday","sequence":"additional","affiliation":[{"name":"1 Division of Hematology and Oncology, Department of Medicine, University of Washington, Seattle, WA"},{"name":"2 Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary-Elizabeth M.","family":"Percival","sequence":"additional","affiliation":[{"name":"1 Division of Hematology and Oncology, Department of Medicine, University of Washington, Seattle, WA"},{"name":"2 Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2025,12,5]]},"reference":[{"issue":"26","key":"2025120616343801000_hem2025000745C1","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1182\/blood.2021013626","article-title":"2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD working party","volume":"138","author":"Heuser","year":"2021","journal-title":"Blood"},{"issue":"15","key":"2025120616343801000_hem2025000745C2","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1200\/JCO.2017.76.3425","article-title":"Measurable residual disease at induction redefines partial response in acute myeloid leukemia and stratifies outcomes in patients at standard risk without NPM1 mutations","volume":"36","author":"Freeman","year":"2018","journal-title":"J Clin Oncol"},{"issue":"2","key":"2025120616343801000_hem2025000745C3","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1002\/hon.2488","article-title":"Prognostic value of multicenter flow cytometry harmonized assessment of minimal residual disease in acute myeloblastic leukemia","volume":"36","author":"Lacombe","year":"2018","journal-title":"Hematol Oncol"},{"issue":"4","key":"2025120616343801000_hem2025000745C4","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1200\/JCO.2015.63.3826","article-title":"Allogeneic hematopoietic cell transplantation for acute myeloid leukemia: time to move toward a minimal residual disease-based definition of complete remission?","volume":"34","author":"Araki","year":"2016","journal-title":"J Clin Oncol"},{"issue":"11","key":"2025120616343801000_hem2025000745C5","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1182\/blood.2021014804","article-title":"Conditioning intensity and peritransplant flow cytometric MRD dynamics in adult AML","volume":"139","author":"Paras","year":"2022","journal-title":"Blood"},{"issue":"9","key":"2025120616343801000_hem2025000745C6","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1038\/s41375-023-01981-2","article-title":"Comparison between measurable residual disease relapse and morphologic relapse in acute myeloid leukemia and high-grade myeloid neoplasms","volume":"37","author":"Shih","year":"2023","journal-title":"Leukemia"},{"issue":"7","key":"2025120616343801000_hem2025000745C7","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1038\/leu.2017.113","article-title":"Measurable residual disease testing in acute myeloid leukaemia","volume":"31","author":"Hourigan","year":"2017","journal-title":"Leukemia"},{"issue":"13","key":"2025120616343801000_hem2025000745C8","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa1716863","article-title":"Molecular minimal residual disease in acute myeloid leukemia","volume":"378","author":"Jongen-Lavrencic","year":"2018","journal-title":"N Engl J Med"},{"issue":"2","key":"2025120616343801000_hem2025000745C9","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1097\/MOH.0000000000000633","article-title":"Germline mutations in MDS\/AML predisposition disorders","volume":"28","author":"Godley","year":"2021","journal-title":"Curr Opin Hematol"},{"issue":"12","key":"2025120616343801000_hem2025000745C10","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1200\/JCO.19.03011","article-title":"Impact of conditioning intensity of allogeneic transplantation for acute myeloid leukemia with genomic evidence of residual disease","volume":"38","author":"Hourigan","year":"2020","journal-title":"J Clin Oncol"},{"issue":"4","key":"2025120616343801000_hem2025000745C11","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1182\/bloodadvances.2020003508","article-title":"Baseline and serial molecular profiling predicts outcomes with hypomethylating agents in myelodysplastic syndromes","volume":"5","author":"Hunter","year":"2021","journal-title":"Blood Adv"},{"issue":"9","key":"2025120616343801000_hem2025000745C12","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1001\/jama.2023.1363","article-title":"DNA sequencing to detect residual disease in adults with acute myeloid leukemia prior to hematopoietic cell transplant","volume":"329","author":"Dillon","year":"2023","journal-title":"JAMA"},{"issue":"8","key":"2025120616343801000_hem2025000745C13","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1182\/bloodadvances.2018015925","article-title":"A next-generation sequencing-based assay for minimal residual disease assessment in AML patients with FLT3-ITD mutations","volume":"2","author":"Levis","year":"2018","journal-title":"Blood Adv"},{"issue":"19","key":"2025120616343801000_hem2025000745C14","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1182\/blood.2024025154","article-title":"Measurable residual disease and posttransplantation gilteritinib maintenance for patients with FLT3-ITD- mutated AML","volume":"145","author":"Levis","year":"2025","journal-title":"Blood"},{"issue":"3","key":"2025120616343801000_hem2025000745C15","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1038\/s41409-023-02189-9","article-title":"Persistent IDH mutations are not associated with increased relapse or death in patients with IDH-mutated acute myeloid leukemia undergoing allogeneic hematopoietic cell transplant with post-transplant cyclophosphamide","volume":"59","author":"Ravindra","year":"2024","journal-title":"Bone Marrow Transplant"},{"issue":"8","key":"2025120616343801000_hem2025000745C16","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1001\/jama.2015.9643","article-title":"Association between mutation clearance after induction therapy and outcomes in acute myeloid leukemia","volume":"314","author":"Klco","year":"2015","journal-title":"JAMA"},{"issue":"1","key":"2025120616343801000_hem2025000745C17","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.bbmt.2016.10.016","article-title":"Factors determining responses to azacitidine in patients with myelodysplastic syndromes and acute myeloid leukemia with early post-transplantation relapse: a prospective trial","volume":"23","author":"Woo","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"issue":"12","key":"2025120616343801000_hem2025000745C18","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1016\/S1470-2045(18)30580-1","article-title":"Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial","volume":"19","author":"Platzbecker","year":"2018","journal-title":"Lancet Oncol"},{"issue":"21","key":"2025120616343801000_hem2025000745C19","doi-asserted-by":"crossref","first-page":"5580","DOI":"10.1182\/bloodadvances.2020002544","article-title":"A phase 3 randomized study of 5-azacitidine maintenance vs observation after transplant in high-risk AML and MDS patients","volume":"4","author":"Oran","year":"2020","journal-title":"Blood Adv"},{"issue":"26","key":"2025120616343801000_hem2025000745C20","doi-asserted-by":"crossref","first-page":"2993","DOI":"10.1200\/JCO.19.03345","article-title":"Sorafenib maintenance after allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia with FLT3-internal tandem duplication mutation (SORMAIN)","volume":"38","author":"Burchert","year":"2020","journal-title":"J Clin Oncol"},{"issue":"5","key":"2025120616343801000_hem2025000745C21","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1056\/NEJMoa1614359","article-title":"Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation","volume":"377","author":"Stone","year":"2017","journal-title":"N Engl J Med"},{"issue":"10388","key":"2025120616343801000_hem2025000745C22","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1016\/S0140-6736(23)00464-6","article-title":"Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"401","author":"Erba","year":"2023","journal-title":"Lancet"},{"issue":"9","key":"2025120616343801000_hem2025000745C23","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1016\/S1470-2045(20)30455-1","article-title":"Sorafenib maintenance in patients with FLT3-ITD acute myeloid leukaemia undergoing allogeneic haematopoietic stem-cell transplantation: an open-label, multicentre, randomised phase 3 trial","volume":"21","author":"Xuan","year":"2020","journal-title":"Lancet Oncol"},{"issue":"15","key":"2025120616343801000_hem2025000745C24","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1200\/JCO.23.02474","article-title":"Gilteritinib as post-transplant maintenance for AML with internal tandem duplication mutation of FLT3","volume":"42","author":"Levis","year":"2024","journal-title":"J Clin Oncol"},{"issue":"suppl 1","key":"2025120616343801000_hem2025000745C25","doi-asserted-by":"crossref","first-page":"2890","DOI":"10.1182\/blood-2024-207305","article-title":"Quantum-first: effects of quizartinib (Q) on RFS, OS, CIR, and MRD in newly diagnosed (nd) patients (pts) with FMS-like tyrosine kinase 3-internal tandem duplication-positive (FLT3-ITD+) acute myeloid leukemia (AML) who received continuation (CONT) therapy (tx)","volume":"144","author":"Levis","year":"2024","journal-title":"Blood"},{"key":"2025120616343801000_hem2025000745C26","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1182\/blood-2024-201694","article-title":"Clearance of leukemia associated mutations (LAMs) after induction therapy is associated with favorable outcomes in intermediate risk acute myeloid leukemia: interim results of a multicenter, prospective phase II trial","volume":"144","author":"Jacoby","year":"2024","journal-title":"Blood"},{"issue":"suppl 1","key":"2025120616343801000_hem2025000745C27","doi-asserted-by":"crossref","first-page":"12973","DOI":"10.1182\/blood-2022-165289","article-title":"Trial in progress: a first-in-human phase 1\/2 study of hematopoietic stem cell transplantation (HCT) with VOR33 (CD33-deleted allograft) followed by treatment with gemtuzumab ozogamicin (GO) in patients with CD33+ acute myeloid leukemia (AML) who are at high-risk of post-HCT relapse","volume":"140","author":"Cooper","year":"2022","journal-title":"Blood"},{"issue":"6","key":"2025120616343801000_hem2025000745C28","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1182\/bloodadvances.2024015441","article-title":"Clinical use of measurable residual disease in adult ALL: recommendations from a panel of US experts","volume":"9","author":"Short","year":"2025","journal-title":"Blood Adv"},{"issue":"13","key":"2025120616343801000_hem2025000745C29","doi-asserted-by":"crossref","first-page":"4006","DOI":"10.1182\/bloodadvances.2022007378","article-title":"High-sensitivity next-generation sequencing MRD assessment in ALL identifies patients at very low risk of relapse","volume":"6","author":"Short","year":"2022","journal-title":"Blood Adv"},{"issue":"20","key":"2025120616343801000_hem2025000745C30","doi-asserted-by":"crossref","first-page":"2771","DOI":"10.1182\/blood-2016-11-749978","article-title":"Monitoring of childhood ALL using BCR-ABL1 genomic breakpoints identifies a subgroup with CML-like biology","volume":"129","author":"Hovorkova","year":"2017","journal-title":"Blood"},{"issue":"8","key":"2025120616343801000_hem2025000745C31","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1002\/ajh.26949","article-title":"Ultrasensitive NGS MRD assessment in Ph+ ALL: prognostic impact and correlation with RT-PCR for BCR::ABL1","volume":"98","author":"Short","year":"2023","journal-title":"Am J Hematol"},{"issue":"26","key":"2025120616343801000_hem2025000745C32","doi-asserted-by":"crossref","first-page":"3140","DOI":"10.1200\/JCO.24.00108","article-title":"Significance of measurable residual disease in adult Philadelphia chromosome-positive ALL: a GRAAPH-2014 study","volume":"42","author":"Kim","year":"2024","journal-title":"J Clin Oncol"},{"issue":"19","key":"2025120616343801000_hem2025000745C33","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1182\/blood.2023020794","article-title":"Diagnosis, prognostic factors, and assessment of ALL in adults: 2024 ELN recommendations from a European expert panel","volume":"143","author":"G\u00f6kbuget","year":"2024","journal-title":"Blood"},{"issue":"3","key":"2025120616343801000_hem2025000745C34","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1182\/blood-2005-07-2708","article-title":"Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia","volume":"107","author":"Br\u00fcggemann","year":"2006","journal-title":"Blood"},{"issue":"6","key":"2025120616343801000_hem2025000745C35","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1038\/s41409-018-0373-4","article-title":"Hematopoietic stem cell transplantation for adults with Philadelphia chromosome-negative acute lymphoblastic leukemia in first remission: a position statement of the European Working Group for Adult Acute Lymphoblastic Leukemia (EWALL) and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT)","volume":"54","author":"Giebel","year":"2019","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"2025120616343801000_hem2025000745C36","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1186\/s12885-018-4670-5","article-title":"Influence of pre-transplant minimal residual disease on prognosis after allo-SCT for patients with acute lymphoblastic leukemia: systematic review and meta-analysis","volume":"18","author":"Shen","year":"2018","journal-title":"BMC Cancer"},{"issue":"14","key":"2025120616343801000_hem2025000745C37","doi-asserted-by":"crossref","first-page":"3395","DOI":"10.1182\/bloodadvances.2023009856","article-title":"Next-generation sequencing-based MRD in adults with ALL undergoing hematopoietic cell transplantation","volume":"7","author":"Liang","year":"2023","journal-title":"Blood Adv"},{"issue":"7","key":"2025120616343801000_hem2025000745C38","doi-asserted-by":"crossref","first-page":"e170580","DOI":"10.1001\/jamaoncol.2017.0580","article-title":"Association of minimal residual disease with clinical outcome in pediatric and adult acute lymphoblastic leukemia: a meta-analysis","volume":"3","author":"Berry","year":"2017","journal-title":"JAMA Oncol"},{"issue":"11","key":"2025120616343801000_hem2025000745C39","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1200\/JCO.2014.58.4631","article-title":"Monitoring of minimal residual disease after allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia allows for the identification of impending relapse: results of the ALL-BFM-SCT 2003 trial","volume":"33","author":"Bader","year":"2015","journal-title":"J Clin Oncol"},{"issue":"3","key":"2025120616343801000_hem2025000745C40","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1111\/bjh.12639","article-title":"Minimal residual disease before and after transplantation for childhood acute lymphoblastic leukaemia: is there any room for intervention?","volume":"164","author":"Balduzzi","year":"2014","journal-title":"Br J Haematol"},{"issue":"10","key":"2025120616343801000_hem2025000745C41","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1016\/j.bbmt.2014.05.026","article-title":"Comparison of chimerism and minimal residual disease monitoring for relapse prediction after allogeneic stem cell transplantation for adult acute lymphoblastic leukemia","volume":"20","author":"Terwey","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"issue":"14","key":"2025120616343801000_hem2025000745C42","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1182\/blood-2017-08-798322","article-title":"Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia","volume":"131","author":"G\u00f6kbuget","year":"2018","journal-title":"Blood"},{"issue":"9","key":"2025120616343801000_hem2025000745C43","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1002\/ajh.26634","article-title":"Blinatumomab is associated with favorable outcomes in patients with B-cell lineage acute lymphoblastic leukemia and positive measurable residual disease at a threshold of 10\u22124 and higher","volume":"97","author":"Jabbour","year":"2022","journal-title":"Am J Hematol"},{"issue":"1","key":"2025120616343801000_hem2025000745C44","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1038\/s41408-022-00766-7","article-title":"Real-world use of blinatumomab in adult patients with B-cell acute lymphoblastic leukemia in clinical practice: results from the NEUF study","volume":"13","author":"Boissel","year":"2023","journal-title":"Blood Cancer J"},{"issue":"1","key":"2025120616343801000_hem2025000745C45","first-page":"234","article-title":"Blinatumomab is associated with better post-transplant outcome than chemotherapy in children with high-risk, first-relapse B-cell acute lymphoblastic leukemia irrespective of the conditioning regimen","volume":"110","author":"Peters","year":"2025","journal-title":"Haematologica"},{"issue":"5","key":"2025120616343801000_hem2025000745C46","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtct.2024.03.004","article-title":"Pretransplant blinatumomab improves outcomes in B cell acute lymphoblastic leukemia patients who undergo allogeneic hematopoietic cell transplantation","volume":"30","author":"Sayyed","year":"2024","journal-title":"Transplant Cell Ther"},{"issue":"4","key":"2025120616343801000_hem2025000745C47","doi-asserted-by":"crossref","first-page":"e070051","DOI":"10.1136\/bmjopen-2022-070051","article-title":"Safety and efficacy of post- haematopoietic cell transplantation maintenance therapy with blinatumomab for relapsed\/refractory CD19-positive B-cell acute lymphoblastic leukaemia: protocol for a phase I-II, multicentre, non-blinded, non-controlled trial (JPLSG SCT-ALL-BLIN21)","volume":"13","author":"Sakaguchi","year":"2023","journal-title":"BMJ Open"},{"issue":"12","key":"2025120616343801000_hem2025000745C48","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1182\/blood.2021013290","article-title":"Blinatumomab maintenance after allogeneic hematopoietic cell transplantation for B-lineage acute lymphoblastic leukemia","volume":"139","author":"Gaballa","year":"2022","journal-title":"Blood"},{"issue":"4","key":"2025120616343801000_hem2025000745C49","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa2312948","article-title":"Blinatumomab for MRD-negative acute lymphoblastic leukemia in adults","volume":"391","author":"Litzow","year":"2024","journal-title":"N Engl J Med"},{"issue":"5","key":"2025120616343801000_hem2025000745C50","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1182\/blood.2023022330","article-title":"Phase 2 study of inotuzumab ozogamicin for measurable residual disease in acute lymphoblastic leukemia in remission","volume":"143","author":"Jabbour","year":"2024","journal-title":"Blood"},{"issue":"6","key":"2025120616343801000_hem2025000745C51","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1182\/bloodadvances.2023011514","article-title":"A multicenter study of posttransplantation low-dose inotuzumab ozogamicin to prevent relapse of acute lymphoblastic leukemia","volume":"8","author":"Metheny","year":"2024","journal-title":"Blood Adv"},{"issue":"20","key":"2025120616343801000_hem2025000745C52","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1182\/blood.2022016194","article-title":"The role of allogeneic transplant for adult Ph+ ALL in CR1 with complete molecular remission: a retrospective analysis","volume":"140","author":"Ghobadi","year":"2022","journal-title":"Blood"},{"issue":"19","key":"2025120616343801000_hem2025000745C53","doi-asserted-by":"crossref","first-page":"2941","DOI":"10.1002\/cncr.30130","article-title":"Use of tyrosine kinase inhibitors to prevent relapse after allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: a position statement of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation","volume":"122","author":"Giebel","year":"2016","journal-title":"Cancer"},{"issue":"8","key":"2025120616343801000_hem2025000745C54","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1200\/JCO.23.01075","article-title":"Long-term results of the dasatinib-blinatumomab protocol for adult Philadelphia-positive ALL","volume":"42","author":"Fo\u00e0","year":"2024","journal-title":"J Clin Oncol"},{"issue":"3","key":"2025120616343801000_hem2025000745C55","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1182\/bloodadvances.2016001495","article-title":"US intergroup study of chemotherapy plus dasatinib and allogeneic stem cell transplant in Philadelphia chromosome positive ALL","volume":"1","author":"Ravandi","year":"2016","journal-title":"Blood Adv"},{"issue":"21","key":"2025120616343801000_hem2025000745C56","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1001\/jama.2024.4783","article-title":"Ponatinib vs imatinib in frontline Philadelphia chromosome-positive acute lymphoblastic leukemia: a randomized clinical trial","volume":"331","author":"Jabbour","year":"2024","journal-title":"JAMA"},{"issue":"15","key":"2025120616343801000_hem2025000745C57","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1016\/S1470-2045(15)00207-7","article-title":"Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 study","volume":"16","author":"Jabbour","year":"2015","journal-title":"Lancet Oncol"},{"issue":"36","key":"2025120616343801000_hem2025000745C58","doi-asserted-by":"crossref","first-page":"4246","DOI":"10.1200\/JCO.24.00272","article-title":"Results of the simultaneous combination of ponatinib and blinatumomab in Philadelphia chromosome- positive ALL","volume":"42","author":"Kantarjian","year":"2024","journal-title":"J Clin Oncol"},{"issue":"11","key":"2025120616343801000_hem2025000745C59","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.3390\/cancers16112108","article-title":"Ponatinib as a prophylactic or pre-emptive strategy to prevent cytological relapse after allogeneic stem cell transplantation in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia transplanted in complete cytological remission","volume":"16","author":"Candoni","year":"2024","journal-title":"Cancers (Basel)"},{"key":"2025120616343801000_hem2025000745C60","doi-asserted-by":"crossref","first-page":"106930","DOI":"10.1016\/j.leukres.2022.106930","article-title":"Safety and outcomes of maintenance therapy with third-generation tyrosine kinase inhibitor after allogeneic hematopoietic cell transplantation in Philadelphia chromosome positive acute lymphoblastic leukemia patients with T315I mutation","volume":"121","author":"Chen","year":"2022","journal-title":"Leuk Res"},{"issue":"15","key":"2025120616343801000_hem2025000745C61","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1182\/blood.2019004685","article-title":"Impact of TKIs post-allogeneic hematopoietic cell transplantation in Philadelphia chromosome-positive ALL","volume":"136","author":"Saini","year":"2020","journal-title":"Blood"},{"issue":"11","key":"2025120616343801000_hem2025000745C62","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1016\/j.bbmt.2019.08.014","article-title":"Hematopoietic cell transplantation in the treatment of adult acute lymphoblastic leukemia: updated 2019 evidence-based review from the American Society for Transplantation and Cellular Therapy","volume":"25","author":"DeFilipp","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"18","key":"2025120616343801000_hem2025000745C63","doi-asserted-by":"crossref","first-page":"5395","DOI":"10.1182\/bloodadvances.2022007764","article-title":"Ponatinib, chemotherapy, and transplant in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"6","author":"Ribera","year":"2022","journal-title":"Blood Adv"},{"issue":"15","key":"2025120616343801000_hem2025000745C64","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1182\/blood-2018-11-883710","article-title":"Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy","volume":"133","author":"Hay","year":"2019","journal-title":"Blood"},{"issue":"14","key":"2025120616343801000_hem2025000745C65","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1182\/blood.2023022922","article-title":"The present and future of CAR T-cell therapy for adult B-cell ALL","volume":"145","author":"Rampotas","year":"2025","journal-title":"Blood"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/hematology\/article-pdf\/2025\/1\/523\/2469746\/523raychaudhuri.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/hematology\/article-pdf\/2025\/1\/523\/2469746\/523raychaudhuri.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T21:34:50Z","timestamp":1765056890000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2025\/1\/523\/556920\/Peri-transplant-conundrums-optimizing-maintenance"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,5]]},"references-count":65,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12,5]]},"published-print":{"date-parts":[[2025,12,5]]}},"URL":"https:\/\/doi.org\/10.1182\/hematology.2025000745","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,12,5]]},"published":{"date-parts":[[2025,12,5]]}}}